Table 3.

Changes in selected metabolic parameters in the Second-Generation Antipsychotic Treatment Indications, Effectiveness and Tolerability in Youth trial44

Atypical antipsychotic	Metabolic parameter (mean change from baseline [95% CI])	P value versus baseline
Glucose (mg/dL)
Aripiprazole	0.54 (−2.85–3.93)	0.76
Olanzapine	3.14 (0.69–5.59)	0.02
Quetiapine	2.64 (−0.65–5.93)	0.12
Risperidone	1.14 (−0.84–3.12)	0.26
Untreated	0.69 (−4.84–6.22)	0.81
Insulin (μIU/mL)
Aripiprazole	2.61 (−2.09–7.31)	0.28
Olanzapine	2.71 (0.42–5.00)	0.02
Quetiapine	1.08 (−2.80–4.96)	0.59
Risperidone	0.69 (−0.86–2.24)	0.39
Untreated	−0.47 (−4.31–3.37)	0.81
Total cholesterol (mg/dL)
Aripiprazole	3.75 (−3.85–11.35)	0.34
Olanzapine	15.58 (6.88–24.28)	<0.001
Quetiapine	9.05 (0.41–17.69)	0.046
Risperidone	3.46 (−1.44–8.36)	0.17
Untreated	2.38 (−7.69–12.45)	0.82
LDL cholesterol (mg/dL)
Aripiprazole	7.38 (0.77–13.99)	0.05
Olanzapine	11.54 (3.97–19.11)	0.004
Quetiapine	3.88 (−3.37–11.13)	0.30
Risperidone	0.21 (−4.14–4.56)	0.92
Untreated	2.99 (−5.18–11.16)	0.49
HDL cholesterol (mg/dL)
Aripiprazole	0.29 (−2.32–2.90)	0.83
Olanzapine	−1.27 (−3.80–1.26)	0.33
Quetiapine	−1.47 (−5.06–2.12)	0.43
Risperidone	0.33 (−1.26–1.92)	0.68
Untreated	1.49 (−3.10–6.08)	0.53
Triglycerides (mg/dL)
Aripiprazole	−2.40 (−19.71–14.91)	0.79
Olanzapine	24.34 (9.80–38.88)	0.002
Quetiapine	36.96 (10.13–63.79)	0.01
Risperidone	9.74 (0.45–19.03)	0.04
Untreated	−11.84 (−41.55–17.87)	0.45

Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein; CI, confidence interval.